Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
June 3, 2019Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
Healthcare would be ‘on the table’ in post-Brexit trade negotiations with US, Trump’s ambassador says
June 3, 2019Sales and Marketing J&J, JJ, NHS, UK, US, brexit, healthcare
The American Ambassador to the United Kingdom has said that Britain’s healthcare system would be ‘on the table’ in post-Brexit …
Dr Dietmar Berger returns to big pharma
May 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atara, R&D, Sanofi, oncology, pharma, research
Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the …
Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis
May 31, 2019Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis
New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …
Top Ten most popular articles on Pharmafile.com this week!
May 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA, GSK, Novartis, Pfizer, environment, opioids, pharma, pricing
The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …
RCP calls on NICE to update guidelines on coming off antidepressants
May 31, 2019Medical Communications Guidelines, NICE, RCP, antidepressants, health, pharma
Guidance for patients on coming off antidepressants needs to be updated, according to the Royal College of Psychiatrists (RCP). Current …
NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant
May 31, 2019Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma
MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
Synthetic, non-intoxicating CBD analogue treats seizures in rats
May 31, 2019Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma
A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …
Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma
May 30, 2019Research and Development Novartis, QVM149, asthma, pharma
Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …
Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
May 30, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
Novo Holdings invests £53.5 million into Oxford Biomedica
May 30, 2019Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup
May 30, 2019Research and Development Janssen, darzalex, pharma
Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …
Oklahoma prosecutors say J&J used ‘brainwashing campaign’ to boost opioid sales
May 30, 2019Research and Development J&J, JJ, opioid crisis, opioids, pharma, public health
Oklahoma state prosecutors have accused Johnson & Johnson of engaging in a “cynical, deceitful, multibillion-dollar brainwashing campaign” to boost sales …
Pharma firms paid Italian doctor to promote opioid drugs
May 29, 2019Research and Development Italy, Mundipharma, Purdue, opioids, pharma
Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for chronic pain, Italian prosecutors say. …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
UK government refuses to sign up to WHO pricing transparency resolution
May 29, 2019Research and Development WHA, WHO, access, health UK, pharma, pricing
The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …
FDA approves Theranica’s smartphone-controlled electroceutical device for migraine
May 29, 2019Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma
Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …
Manchester emerges as genomics research hub
May 29, 2019Research and Development Diagnostics, Manchester, UK, genomics, pharma
Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration …
Living with Scimitar syndrome
May 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scimitar syndrome, patient experience, pharma
Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
